Moderna (NASDAQ:MRNA) Stock Rating Lowered by Barclays

Moderna (NASDAQ:MRNA) was downgraded by Barclays from an “overweight” rating to an “equal weight” rating in a research note issued on Tuesday,Briefing.com Automated Import reports. They presently have a $45.00 target price on the stock, down from their prior target price of $111.00. Barclays‘s target price suggests a potential upside of 36.40% from the stock’s current price.

MRNA has been the subject of several other reports. Hsbc Global Res upgraded Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Berenberg Bank raised their price objective on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. JPMorgan Chase & Co. reduced their target price on Moderna from $59.00 to $45.00 and set an “underweight” rating for the company in a research note on Tuesday, November 26th. Evercore ISI decreased their price target on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating for the company in a research report on Monday, January 27th. Finally, Wolfe Research began coverage on shares of Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Moderna currently has a consensus rating of “Hold” and an average price target of $63.42.

Moderna Price Performance

Shares of MRNA stock opened at $32.99 on Tuesday. The firm has a fifty day simple moving average of $38.61 and a 200-day simple moving average of $53.82. The company has a market capitalization of $12.70 billion, a PE ratio of -5.67 and a beta of 1.59. Moderna has a twelve month low of $29.25 and a twelve month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 2,664 shares of company stock valued at $115,210. Company insiders own 15.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Voloridge Investment Management LLC boosted its position in shares of Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock valued at $107,727,000 after purchasing an additional 1,996,003 shares in the last quarter. Woodline Partners LP boosted its holdings in Moderna by 8.3% during the fourth quarter. Woodline Partners LP now owns 142,523 shares of the company’s stock worth $5,926,000 after buying an additional 10,968 shares in the last quarter. Two Sigma Investments LP grew its position in Moderna by 5.8% in the fourth quarter. Two Sigma Investments LP now owns 664,040 shares of the company’s stock worth $27,611,000 after buying an additional 36,558 shares during the last quarter. Theleme Partners LLP increased its holdings in shares of Moderna by 1.0% in the fourth quarter. Theleme Partners LLP now owns 7,306,861 shares of the company’s stock valued at $303,819,000 after buying an additional 72,028 shares in the last quarter. Finally, Tang Capital Management LLC acquired a new stake in shares of Moderna during the 4th quarter valued at $12,474,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.